Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triac therapy in Allan-Herndon-Dudley syndrome (MCT8 deficiency)
2014-000178-20Phase 2Completed
- Sponsor
- Erasmus MC
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiratricol in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Erasmus MC. Primary endpoints: Serum thyroid hormone parameters and Neurological phenotype. Started Jun 2015; status: completed.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on 2014-000178-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000178-20.